Dual HER2 blockade with trastuzumab and pertuzumab alone in the absence of cytotoxic chemotherapy has shown reasonable pathological response rates (16.8%) in patients with locally advanced or inflammatory, operable, HER2+ breast cancer [7]. This evidence concerns the gene ERBB2 and breast carcinoma.